MedTrace Logo

TWB-103 for Treating Lower Limb Ulcers on Patients With DM

NCT03624023 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-07-12

Study results available
· View outcomes & findings →

Summary

Primary Objective:

To assess the safety profile of TWB-103 administered to subjects with diabetic lower limb ulcers

Secondary Objective:

To explore the efficacy of TWB-103 administered to subjects with diabetic lower limb ulcers

Conditions

  • Diabetic Foot Ulcer

Interventions

DRUG

TWB-103

TWB-103 will be applied to the target ulcer wound once a week by the investigator, starting from Day 1, until wound closure is confirmed or up to 12 weekly applications

Sponsors & Collaborators

  • Transwell Biotech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Niann-Tzyy Dai, PhD · Tri-Service General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-19
Primary Completion
2021-07-09
Completion
2021-07-09
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03624023 on ClinicalTrials.gov